SURVYR

BMEA

Biomea Fusion, Inc.
$0.65
+$0.01 (0.89%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-59%-30%-1%+28%+58%Oct 2025Oct 2026Apr 202652w high $2.2452w low $0.74
BMEASPY
Wall St. Highest PT $10.00 (+1443.9%) Wall St. Avg PT $6.17 (+852.1%)
$1$4$7$10$14POC $1Hi $10Avg $6
Underwater Drawdown %Max DD -73.5%Current -70.7%
0.0%-73.5%
Relative Strength vs SPY-68.3% vs SPYUnderperforming
+82%0%-82%
1W
−$0.04 (6.13%)
1M
−$0.64 (49.79%)
3M
−$0.57 (46.91%)
6M
−$0.80 (55.33%)
YTD
−$0.59 (47.77%)
1Y
−$0.73 (53.07%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
7 analysts · mean score 1.71
1 = Strong Buy · 5 = Sell
Strong Buy457%
Buy229%
Hold00%
Underperform114%
Sell00%
Wall Street consensus · as of Oct 16, 2026
Analyst price targets
Current price$0.65
Average target$6.17
+$5.52 (+852.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$4.00
Median$6.00
High$10.00
12-month Wall Street target range · as of Oct 16, 2026
Recent analyst rating changes · 8
Reiterated
2026-10-14 · Citizens reiterated Market Outperform on BMEA
Reiterated
2026-10-14 · HC Wainwright & Co. reiterated Buy on BMEA
Initiated
2026-10-07 · Brookline Capital started covering BMEA at Buy
Initiated
2026-05-05 · Citizens started covering BMEA at Market Outperform
Reiterated
2026-04-28 · D. Boral Capital reiterated Buy on BMEA
Reiterated
2026-04-08 · D. Boral Capital reiterated Buy on BMEA
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$53.2M
P/E (next 12 months, estimated)-0.8
52-week range$0.74 – $2.24
Dividend yieldNo dividend
Analyst consensusBuy (6)
Average analyst price target$6.17 (+852%)

What they do

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for BMEA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

BMEA earningsNext report in 6 days
Next report · quarter Sep 2026
Tue Nov 3, 2026Time not confirmed
EPS consensus-$0.22 range -$0.28–-$0.17
Revenue consensus$0 7 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$0.17est -$0.23+25.6%Above estimates
May 11, 2026-$0.17est -$0.19+10.3%Above estimates
Mar 24, 2026-$0.12est -$0.22+45.6%Above estimates
Nov 4, 2025-$0.24est -$0.29+17.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 01:29:51 ET
24-1025-0325-0525-0825-1126-0326-0526-08-0.930.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Top Premarket Decliners
MT Newswires · Oct 14
Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
MarketBeat · Oct 13
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
GlobeNewswire · Oct 13
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
GlobeNewswire · Oct 12
Sector Update: Healthcare Stocks Decline Late Afternoon
MT Newswires · Sep 23
Rating changes
Reiterated
2026-10-14 · Citizens reiterated Market Outperform on BMEA
Reiterated
2026-10-14 · HC Wainwright & Co. reiterated Buy on BMEA
Initiated
2026-10-07 · Brookline Capital started covering BMEA at Buy
Initiated
2026-05-05 · Citizens started covering BMEA at Market Outperform
Reiterated
2026-04-28 · D. Boral Capital reiterated Buy on BMEA
Reiterated
2026-04-08 · D. Boral Capital reiterated Buy on BMEA

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 01:29:51 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026